API Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (Websockets) API Financial News API Delisted Data API
Solutions
New & Popular APIs
Show all APIs Fundamental Data APIs Historical End-of-Day API Real-time Prices API Financial Events & News API Indices Historical Constituents API 40 000 Stock Market Logos API Forex Data APIs
Other products
Google Sheets Add-on Excel Add-on Coding Libraries (Python, R, etc) Wordpress Add-on
API Marketplace
Community
Academy 152 articles Forum Github 14 repos
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. SHE /
  3. 300142.SHE

Walvax BioTech (300142 SHE) stock market data APIs

¥15.33 0.87(6%) as of November 22, 2024
Price chart is built with Anychart

Walvax Biotechnology Co., Ltd., researches, develops, produces, and markets vaccines in China. The company offers SARS-CoV-2 mRNA vaccine, an immunization to prevent COVID-19 to individuals 18 years of age and older; 13-valent pneumococcal polysaccharide conjugate vaccine, an invasive diseases caused by streptococcus pneumoniae for use in infants and children 6 weeks through 5 years of age; and recombinant human papillomavirus bivalent vaccine, for the prevention of cervical cancers and precancerous lesions caused by human; 23-valent pneumococcal polysaccharide vaccine, for individuals age 2 years of pneumococcal diseases; ACYW135 meningococcal polysaccharide vaccine, for the prevention of invasive meningococcal diseases; Group A and C meningococcal polysaccharide vaccine, for in adults and children over the age of 2 years and adults to prevent disease caused by the bacterium neisseria meningitidis; Group A and Group C meningococcal conjugate vaccine, for the prevention of invasive meningococcal diseases caused by Neisseria meningitidis serogroups A and C for children 3 months through 5 years of age. It also provides haemophilus influenzae type b conjugate vaccine, for the prevention of invasive infections for children 2 months through 5 years of age; diphtheria, tetanus, and acellular pertussis combined vaccine, for diphtheria and tetanus for infants and children 3 months through 6 years of age. Walvax Biotechnology Co., Ltd. was founded in 2001 and is headquartered in Kunming, China.

Walvax BioTech Financial Data Overview

14.46
15.33
-
15.33
14.41
9.78-25.4309
23 127 M
180.75
1 599 M
3 097 M
0.05
0.0007
0.688
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: '300142',
Type: 'Common Stock',
Name: 'Walvax BioTech',
Exchange: 'SHE',
CurrencyCode: 'CNY',
CurrencyName: 'Renminbi',
CurrencySymbol: '¥',
CountryName: 'China',
CountryISO: 'CN',
OpenFigi: NULL,
ISIN: 'CNE100000WN2',
CIK: NULL,
EmployerIdNumber: '',
FiscalYearEnd: 'December',
IPODate: '2010-11-12',
InternationalDomestic: 'International',
Sector: 'Healthcare',
Industry: 'Drug Manufacturers - Specialty & Generic',
}

Walvax BioTech Fundamental Data is available in our Financial Data APIs

  • Net Revenue 3 097 M
  • EBITDA 670 M
  • Earnings Per Share 0.08
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Walvax BioTech Earnings via APIs

  • Latest Release 2024-10-24
  • EPS/Forecast 0.06

Get Walvax BioTech End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Walvax BioTech latest news via APIs

FOCUS-China's drugmakers can't sell mRNA shots but haven't quit yet

By Andrew Silver SHANGHAI/SUZHOU, China, April 19 (Reuters) - China's vaccine developers stuck with unused mRNA COVID shots and idle manufacturing plants are pursuing new targets for the novel messen...

Indonesia Approves Chinese mRNA Vaccine

Indonesia became the first country to give regulatory go-ahead to a Chinese-made mRNA Covid-19 vaccine for emergency use, marking potential progress in Beijing’s push to catch up with Western vaccine technology. Continue reading
  • CHINA
  • CLINICAL TRIALS
  • EFFICACY RATE
  • INDONESIA
  • MAINLAND CHINA
  • MRNA
  • MRNA VACCINE
  • VACCINE TECHNOLOGY
News API is available at any package from $19.99 See full price
Get sample of News API
Do you have any questions?
support@eodhistoricaldata.com